Fluticasone/salmeterol pMDI - Cost-effective inhaler choices• Deprescribe: NSAIDs and COX-2 inhibitors• NICE Guidance Recently published• *No Managed Entry Decisions this month*• Methocarbamol — not for long term use• Did you see? Valproate in men — reproductive risks
• What is chronic pain?• How should chronic pain be managed?• Types of chronic pain• Patient education• Alternative strategies to manage chronic pain• Reducing risks — Key points (opioids and gabapentinoids)• Modified-release opioids – Increased dependence risk• Risky opioid combinations• Lidocaine plasters• Further resources
• Travelling Abroad: Vaccine and Health Advice• Patient Information Leaflet Tirzepatide (Mounjaro®) for Obesity• Managed Entry Decisions• NICE Guidance Recently Published• New section on Primary Care Antimicrobial Guideline: Definitions for Antibiotic Susceptibility Reporting• Deprescribe: Omega-3 Fatty Acid Compounds
AIR and MART for Asthma – New NICE/BTS/SIGN Guidance; Recommendations from the guidance; NI Formulary Inhaler options for AIR / MART regime; Reminder: Inhaler Technique; SABA Overprescribing in Asthma -Risks from overuse and changes in SABA prescribing guidelines; Identifying overuse of SABA inhalers; The 5 things prescribers can do that will make a difference; Reduce Your Carbon Footprint !Correctly Dispose of Your Inhalers
• New: HSC Guideline on the use of Proton Pump Inhibitors in PaediatricsUpdates to NI Management of Infection Guidelines for Primary Care; NICE Guidance Recently Published; Managed Entry Decisions; GLP-1 and dual GIP/GLP-1 receptor agonists and hormonal therapies; Lansoprazole dosing error in a baby
